Baclofen Withdrawal Syndrome Clinical Trial
Official title:
Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers
The primary objective of this study is to characterize baclofen pharmacokinetics following
oral and intravenous administration in patients who are on chronic oral baclofen therapy.
The secondary objective is to determine the safety profile of an IV baclofen formulation.
This study is a randomized crossover study with two treatment arms. All subjects will
receive a dose of oral baclofen and a dose of IV baclofen on separate study days. Whether
the oral or intravenous form is given on the first study day will be randomized in a 1:1
manner.
The pharmacokinetic and tolerability information gained from this study will support the
development of further studies to assess the use of IV baclofen to prevent or treat baclofen
withdrawal syndrome.
| Status | Completed |
| Enrollment | 12 |
| Est. completion date | January 2014 |
| Est. primary completion date | January 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: Subjects will be eligible to participate in the study if all of the following conditions exist: 1. Males and females between the ages of 18-65. 2. Subjects are capable of giving informed consent. 3. Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide. 4. Subject should be medication free, other than study drug, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI. Exclusion Criteria: Subjects will be excluded from participation in the study if any of the following conditions exist: 1. Women who are pregnant. 2. Women who are breast feeding. 3. Subject has a history of intolerance to IV administration of medication. 4. Subject has a known hypersensitivity to baclofen. 5. Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease 6. Subject has taken or used any investigational drug or device in the 30 days prior to screening. 7. Subject has taken either prescribed or over the counter medication for 48 hours prior to baclofen administration on either of the study days. 8. Subject reveals clinically significant abnormalities on screening laboratory tests. 9. Subject is a non-English speaker, such that ability to ascertain neurological status would require an interpreter. |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Minnesota | Minneapolis | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| University of Minnesota - Clinical and Translational Science Institute | Paralyzed Veterans of America Research Foundation |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | oral bioavailability | oral bioavailability is the fraction of an administered dose of unchanged drug that reaches the systemic circulation | 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration | No |
| Primary | Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] | AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8). | 5, 15, 30 min and 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration | No |
| Primary | Plasma Decay Half-Life (t1/2) | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. | 5, 15, 30 min and 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration | No |
| Primary | Maximum concentration (Cmax) | The maximum concentration is the maximum baclofen concentration observed | 5, 15, 30 min and 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration | No |
| Primary | Tmax | Tmax is the time at which the maximum baclofen concentration was observed | 5, 15, 30 min and 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration | No |
| Secondary | assessment of sedation | Sedation will be measured using the Stanford Sleepiness Scale. | up to 12 hours | Yes |
| Secondary | Ataxia | A rating scale of ataxia will be used: 0=none, 1=mild, 2=severe For those who are ambulatory, this will be assessed by gait. Ratings will be: mild-unsteady with tandem gait testing, but able to perform without assistance severe-unable to perform tandem gait testing without assistance. For non-ambulatory subjects, ataxia will be assessed by finger to nose and finger pursuit maneuvers. |
up to 12 hours after infusion | Yes |
| Secondary | Nystagmus | Nystagmus will be measured using the following scale. 0=none, 1=mild, 2=severe mild-present on extreme gaze; severe-present on midline gaze | up to 12 hours following drug administration | Yes |
| Secondary | blood pressure | diastolic and systolic blood pressure will be measured | 5 minutes immediately prior to, and during the IV infusion and oral administration, then every 15 minutes for 1 hour, then every hour for 12 hours. | Yes |